Prescription Drugs

PreclinicalSmall molecule

Prescription Drugs is one of 48 small molecule programs targeting Myocardial Infarction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

89 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Praluent

Regeneron

Approved

1 2

Niacor

Neoral

Adenocard

Kengreal

Chiesi Farmaceutici S.p.A.

Approved

2 6

Alka-Seltzer

AAbbott

Approved

1 7

Coreg

Akero Therapeutics

Approved

1 8

Reglan

IIstituto Clinico Humanitas

Approved

1 9

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Benicar

CCosette Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Not yet recruiting

Myocardial Infarction

NCT06717204

Q1 2030

Recruiting

Breast

NCT07346716

Clinical

Trials by Indication[1]

Myocardial Infarction1 trial

Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

Not yet recruiting·QQilu Hospital of Shandong University··NCT06717204·210 enrolled

Breast1 trial

Medicines in Breast Milk and Estimated Infant Exposure

Recruiting·UUniversity Hospital Bispebjerg and Frederiksberg··NCT07346716·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Prescription Drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prescription Drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prescription Drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Hospital of Shandong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: QQilu Hospital of Shandong University

Prescription Drugs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2030

Trials by Indication[1]

Myocardial Infarction1 trial

Breast1 trial

References

Drug Info

Quick Facts

Related News